| [1] |
Seaberg EC,Belle SH,Beringer KC, et al. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin transpl, 1998: 17-37.
|
| [2] |
O′Grady JG,Smith HM,Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol, 1992, 14(1): 104-111.
|
| [3] |
Samuel D,Muller R,Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med, 1993, 329(25): 1842-1847.
|
| [4] |
Ghany MG,Ayola B,Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology, 1998, 27(1): 213-222.
|
| [5] |
Protzer-Knolle U,Naumann U,Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology, 1998, 27(1): 254-263.
|
| [6] |
Brind A,Jiang J,Samuel D, et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol, 1997, 26(2): 228-235.
|
| [7] |
Prieto M,Gómez MD,Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl, 2001, 7(1): 51-58.
|
| [8] |
Manzarbeitia C,Reich DJ,Ortiz JA, et al. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl, 2002, 8(6): 556-561.
|
| [9] |
Yu AS,Vierling JM,Colquhoun SD, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl, 2001, 7(6): 513-517.
|
| [10] |
Joya-Vazquez PP,Dodson FS,Dvorchik I, et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation, 2002, 73(10): 1598-1602.
|
| [11] |
Celebi Kobak A,Karasu Z,Kilic M, et al. Living donor liver transplantation from hepatitis B core antibody positive donors. Transplant Proc, 2007, 39(5): 1488-1490.
|
| [12] |
Cholongitas E,Papatheodoridis GV,Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol, 2010, 52(2): 272-279.
|
| [13] |
González-Peralta RP,Andres JM,Tung FY, et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation, 1994, 58(1): 114-116.
|
| [14] |
Franchello A,Ghisetti V,Marzano A, et al. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl, 2005, 11(8): 922-928.
|
| [15] |
Hwang S,Lee SG,Park KM, et al. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor liver graft. Liver Transpl, 2006, 12(6): 993-997.
|
| [16] |
Loggi E,Bihl F,Chisholm JV 3rd, et al. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol, 2009, 50(3): 625-630.
|
| [17] |
Soejima Y,Shimada M,Taketomi A, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int, 2007, 27(9): 1282-1286.
|
| [18] |
Phillips MJ,Cameron R,Flowers MA, et al. Post-transplant recurrent hepatitis B viral liver disease: viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol, 1992, 140(6): 1295-1308.
|
| [19] |
Terrault NA,Zhou S,Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology, 1996, 24(6): 1327-1333.
|
| [20] |
McGory RW,Ishitani MB,Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with agressive passive immunization. Transplantation, 1996, 61(9): 1358-1364.
|
| [21] |
Samuel D,Bismuth A,Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet, 1991, 337(8745): 813-815.
|
| [22] |
Davies SE,Portmann BC,O′Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology, 1991, 13(1): 150-157.
|
| [23] |
Johnson PJ,Wansbrough-Jones MH,Portmann B, et al. Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. Br Med J, 1978, 1(6107): 216.
|
| [24] |
Lauchart W,Müller R,Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc, 1987, 19(5): 4051-4053.
|
| [25] |
Perrillo RP,Wright T,Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology, 2001, 33(2): 424-432.
|
| [26] |
Lo CM,Cheung ST,Lai CL, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg, 2001, 233(2): 276-281.
|
| [27] |
Jiao ZY,Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc, 2007, 39(5): 1533-1536.
|
| [28] |
Neff GW,0′brien CB,Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl, 2004, 10(11): 1372-1378.
|
| [29] |
Angus PW,McCaughan GW,Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl, 2000, 6(4): 429-433.
|
| [30] |
Han SH,Martin P,Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl, 2003, 9(2): 182-187.
|
| [31] |
Zheng S,Chen Y,Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl, 2006, 12(2): 253-258.
|
| [32] |
Jiang L,Yan L,Li B, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant, 2010, 10(8): 1861-1869.
|
| [33] |
Lo CM,Liu CL,Lau GK, et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefo-vir dipivoxil plus lamivudine. Liver Tranap1, 2005, 11(7): 807-813.
|
| [34] |
Angus PW,Patterson SJ,Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology, 2008, 48(5): 1460-1466.
|
| [35] |
Zoulim F,Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 2009, 137(5): 1593-1608, e1-e2.
|
| [36] |
Coffin CS,Mulrooney-Cousins PM,van Marle G, et al. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl, 2011, 17(8): 955-962.
|